Entweder 10000% oder Totalverlust
Wer je etwas über die Arivaner wissen will, der brauch nur diesen Thread durchlesen und auf das Ergebnis zu schauen. Und dabei ist das hier noch ziemlich harmlos. Die allermeisten haben schließlich ihr ganzes Geld schon vor 2 Jahren verloren und sind schon lange nicht mehr anwesend.
Über den allgemeinen Intellekt hier darf sich dann jeder selbst seine Meinung bilden.
Psychologisch aber äußerst interessant.
gruß hannes
gruß hannes
Aber wehe die fahnen drehen in den WIND was dann, dann sagen solche leute (dr.ix) auf einmal wo habt ihr nur diese super Tipps her.
Nein sage ich da Ariva ist schon klasse, man muß halt nur wissen das eine Aktienanlage immer spekulativ ist.
Ich bleibe dabei Caly ist super-spekulativ alles oder nichts, habe nie gesagt man soll mit seinen ganzen vermögen investiert sein, nein nur einen kleinen teil( LOTTOSCHEIN) obwohl hier die chance sehr viel größer ist.
gruß Grenke
Wäre genau richtig gewesen, bin aber nicht rein.
Gruß
AUF GEHT`S
was soll mir also noch passieren kann ja nur gut gehen.
gruß grenke
Euer masteruz
P.S.: Es gibt nur eine Richtung, nämlich nach Norden!
Euer masteruz
Jan 27, 2003 (M2 PRESSWIRE via COMTEX) -- This company profile for Calypte
Biomedical Corp is taken directly from the BiotechWatch database.
The BiotechWatch database is a continuously updated interactive database that
follows such parameters as products under development, status of clinical
trials, cash on hand, burn rate, and upcoming clinical milestones for over 5000
products from more than 600 biotech and medical device companies.
This user-friendly Calypte Biomedical Corp company profile tracks products in
clinical development, cash on hand, clinical trial status, milestones, corporate
alliances, and current stock prices and fundamentals.
This information is of particular interest to those investing in the
biotechnology sector, industry professionals, and fund managers.
Each profile includes the following -
Company fundamentals: Stock price 52 week high and low price Shares outstanding
Cash on hand Years of cash Market capitalization Daily trading volume
Derived statistics: Market cap / cash on hand Market cap less cash on hand Price
less cash value per share Cash value per share (cash / shares out) Price / 52
week range 52 week high / price 52 week low / price 52 week high less price
Price less 52 week low
Company Information: Clinical trial phases (for each product in development)
Total number of products Total number of clinical trials Medical specialties
Diseases and conditions treated Expected development milestones
A Note on Biotech Company Profiles:
Valuations of most biotech companies are determined by the perceived value of
their technology, the success of their clinical trials, the breadth of the
clinical market being addressed, their likely competitors, the strength of the
strategic partnerships they have forged, the depth of their research and
clinical pipelines, and their current financing.
These company profiles allow you to carefully monitor these parameters across
the biotechnology sector. They allow investors and industry professionals to
make the most informed decisions possible.
The profiles can be used as a basic research tool to access information such as
cash-on-hand, milestones, trading volume, and products under development for a
specific disease or medical indication. These latter parameters provide
information regarding potential competitors and/or partners in specific
development areas. As the timeliness of this information is of paramount
importance, the BiotechWatch staff updates all clinical trial information daily
and financial information such as stock price, market cap, shares outstanding,
52 week high and low and their derivative values are updated every 5
ALAMEDA, Calif., Jan 27, 2003 (BUSINESS WIRE) -- Calypte Biomedical Corporation
(OTCBB: CALY), the developer and marketer of the only two FDA approved HIV-1
antibody tests that can be used on urine samples, as well as an FDA approved
serum HIV-1 antibody Western blot supplemental test, today announced that a
recent study from The Johns Hopkins University utilized Calypte's HIV-1 EIA and
Western Blot Urine tests to determine that urine-based HIV screening is
effective.
The study entitled Screening for HIV Infection in High-Risk Communities by Urine
Antibody Testing published in the December 2002 volume of the JAIDS Journal of
Acquired Immune Deficiency Syndromes concluded that, "Urine-based screening for
HIV infection in high-prevalence inner city communities can be an effective tool
for identifying and treating infected persons who are unaware of their
infection." The study screened 1,718 people from February 1998 to August 2001.
It also mentioned that, "Although it is believed that targeting of known
prevention strategies to those persons of highest risk could significantly
reduce the number of new cases of HIV infection each year, a major barrier to
such targeting is the estimated 300,000 people infected in the United States who
are unaware that they are infected. Therefore, there is an urgent need for new
methods to screen and test populations at high risk for this infection."
"We are very excited that third party analyses, like the Hopkins study, continue
to recognize the merits of urine-based testing," said Dr. Toby Gottfried, Chief
Science Officer at Calypte. "Of the 1,718 persons tested, 210 (12%) were
identified as HIV-1 positive, including 169 persons either never tested or
previously HIV negative. This study's findings are consistent with those
observed in other post market studies completed for our FDA-approved urine test
which found that the availability of urine-based testing as an option resulted
in greater acceptance of voluntary testing."
Nancy Katz, President and CEO of Calypte, stated, "This study reinforces the
'urgent need' to create alternative HIV testing options for high-risk
populations. We believe Calypte fulfills that need by offering a completely
non-invasive, safe and cost effective option with none of the risks associated
with blood testing."
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 4, December
1, 2002 published Screening for HIV Infection in High-Risk Communities by Urine
Antibody Testing by members of the Departments of Molecular Microbiology and
Immunology and Epidemiology, Bloomberg School of Public Health, and Division of
Infectious Diseases, School of Medicine, The Johns Hopkins University,
Baltimore, and National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, Maryland, U.S.A.
Euer masteruz
gruß Grenke
wahnsinn da wird die fa. im mom nur noch mit 10mio$ bewertet, 1 guter auftrag und die sind durch.
Euer masteruz